95 filings
Page 5 of 5
6-K
tzhj84giqar8pwuk
26 Jun 19
Current report (foreign)
5:16pm
6-K
xh6 oyos6gnq
25 Jun 19
ERYTECH Announces Opening of Operations at its New
12:00am
6-K
yzlxewqln48n1m32od
7 Jun 19
Reports Financial Results for First Quarter 2019
4:51pm
6-K
fzpx07h bxkd6l
4 Jan 19
Unaudited Interim Condensed Consolidated Statements of Financial Position
8:51am
6-K
opznh4 acwhi
17 Jul 18
ERYTECH Pharma Reports Voting Results from
4:56pm
6-K
0uces nmo6rei8gu3
25 Jun 18
Current report (foreign)
6:06am
6-K
mzjhhpyjuzh4
15 Jun 18
ERYTECH to Present Preclinical and Clinical Data on Use
12:00am
6-K
glhnq7bf
7 Jun 18
Current report (foreign)
7:03am
6-K
6jdcws4z0 s0sgcw
4 Jun 18
ERYTECH to Present Pharmacodynamic Data from
12:00am
6-K
8trmsrondn63pzzidg
14 May 18
Appointment of Alex Dusek as VP of Commercial Strategy
4:57pm
6-K
rf6t89xo8co8m2shzz
12 Apr 18
ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and NewPre-clinical Data at AACR 2018
12:00am
6-K
c1npzcyx2c
12 Mar 18
Reports Financial Results for Full Year 2017
12:00am
6-K
s5ft3
13 Feb 18
Erytech Pharma 6-K
12:00am
6-K
59az6nf qa7hd
8 Dec 17
ERYTECH ReportsTop-line Results of Phase 2b Study of Eryaspase for the Treatment of AML
12:00am
6-K
w1pd0 t5proayhuk3pun
7 Dec 17
Unaudited Interim Condensed Consolidated Statements of Financial Position
12:00am